SEARCH

SEARCH BY CITATION

References

  • Australian Adverse Drug Reactions Advisory Committee (ADRAC). Zolpidem and bizarre sleep related effects. Aust. Adv. Drug React. Bull., 2007, 26: 2.
  • Dolder, C. and Nelson, M. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs, 2008, 22: 10211036.
  • Edwards, I. R. and Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000, 356: 125512159.
  • Espie, C. ‘Stepped care’: a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep, 2009, 32: 15491558.
  • Ganzoni, E., Santoni, J., Chevillard, V., Sébille, M. and Mathy, B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J. Int. Med. Res., 1995, 23: 6173.
  • Hajak, G. and Bandelow, B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int. Clin. Psychopharmacol., 1998, 13: 157167.
  • Hollingworth, S. A. and Siskind, D. J. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol. Drug Saf., 2010, 19: 280288.
  • Hoque, R. and Chesson, A. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J. Clin. Sleep Med., 2009, 5: 471476.
  • Hwang, T.-J., Ni, H.-C., Chen, H.-C., Lin, Y.-T. and Liao, S.-C. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. J. Clin. Psychiatry, 2010, 71: 13311335.
  • Institute of Medicine (USA). Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Institute of Medicine, Washington, DC, 2006.
  • Landolt, H.-P., Roth, C., Dijk, D.-J. and Borbely, A. A. late-afternoon ethanol intake affects nocturnal sleep and the sleep EEG in middle-aged men. J. Clin. Psychopharmacol., 1996, 16: 428436.
  • Landolt, H. P., Finelli, L. A., Roth, C., Buck, A., Achermann, P. and Borbély, A. A. Zolpidem and sleep deprivation: different effect on EEG power spectra. J. Sleep Res., 2000, 9: 175183.
  • Li, S., Zhang, B., Li, A. and Wing, Y. Prevalence and correlates of frequent nightmares: a community-based 2-phase study. Sleep, 2010, 33: 774780.
  • Mancini, J., Thirion, X., Masut, A. et al. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol. Drug Saf., 2006, 15: 494503.
  • Markowitz, J. S. and Brewerton, T. D. Zolpidem-induced psychosis. Ann. Clin. Psychiatry, 1996, 8: 8991.
  • Matwiyoff, G. and Lee-Chiong, T. Parasomnias: an overview. Ind. J. Med. Res., 2010, 131: 333337.
  • Mendelson, W. B. Sleepwalking associated with zolpidem. J. Clin. Psychopharmacol., 1994, 14: 150.
  • Monti, J., Alvariño, F. and Monti, D. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia. Sleep, 2000, 23: 10751084.
  • Morgenthaler, T. I. and Silber, M. H. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med., 2002, 3: 323327.
  • Morin, C. M., Vallieres, A., Guay, B. et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA, 2009, 301: 20052015.
  • NIH Statement Regarding Treatment of Insomnia. National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Sleep, 2005, 28: 10491057.
  • Olson, L. Hypnotic hazards: adverse effects of zolpidem and other z-drugs. Aust. Prescriber, 2008, 31: 146149.
  • Ozminkowski, R., Wang, S. and Walsh, J. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep, 2007, 30: 263273.
  • Pressman, M. R., Mahowald, M. W., Schenck, C. H. and Bornemann, M. C. No scientific evidence that alcohol causes sleepwalking. J. Sleep Res., 2008, 17: 473474.
  • Roy, A. N. and Smith, M. Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization. Sleep Med., 2010, 11: 462469.
  • Salmerón-García, A., Barrera, J., Pavón, M. et al. Detection of adverse drug reactions through the minimum basic data set. Pharm. World Sci., 2010, 33: 322328.
  • Sauvanet, J., Maarek, L., Roger, M., Renaudin, J., Louvel, E. and Orofiamma, B. Open long-term trials with zolpidem in insomnia. In: J. Sauvanet, S. Langer and P. Morselli (Eds) Imidazopyridines in Sleep Disorders. Raven Press, New York, 1988: 339349.
  • Schenck, C., Connoy, D. and Castellanos, M. Zolpidem-induced sleep related eating disorder (SRED) in 19 patients. Sleep, 2005, 28: A259.
  • Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C. and Sateia, M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J. Clin. Sleep Med., 2008, 4: 487504.
  • Simon, G. and Vonkorff, M. Prevalence, burden, and treatment of insomnia in primary care. Am. J. Psychiatry, 1997, 154: 14171423.
  • Tsai, J.-H., Yang, P., Chen, C.-C. et al. Zolpidem-induced amnesia and somnambulism: rare occurrences? Eur. Neuropsychopharmacol., 2009, 19: 7476.
  • Van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R. and Egberts, A. C. G. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf., 2002, 11: 310.
  • Wing, Y., Lam, S., Li, S., Zhang, J. and Yu, M. Sleep-related eating disorder and zolpidem: an open interventional cohort study. J. Clin. Psychiatry, 2010, 71: 653656.